新型重组带状疱疹疫苗及其制备与应用
The recombinant shingles vaccine with MF59/CpG1009 adjuvant combines the varicella-zoster virus glycoprotein gE protein and the Fc region of human immunoglobulin IgG with a chimeric epitope that activates cellular immunity, thus solving the problems of poor protein activity and large side effects of existing vaccines and achieving more efficient immune protection and fewer side effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHENGDU NANOMICROGEN BIOTECH CO LTD
- Filing Date
- 2024-10-22
- Publication Date
- 2026-07-17
AI Technical Summary
Existing shingles vaccines suffer from poor protein activity, unsatisfactory immune effects, and significant side effects caused by adjuvants, especially in the elderly. There is a need to develop safer vaccines with better immune protection.
The recombinant herpes zoster vaccine using MF59/CpG1009 adjuvant utilizes a fusion protein as an antigen, containing the Fc region of varicella-zoster virus glycoprotein gE and human immunoglobulin IgG, and binds to a chimeric epitope that activates cellular immunity. The combination of MF59 and CpG1009 adjuvants enhances the safety and efficacy of the immune response.
It improved the immunoprotective effect of the shingles vaccine, reduced side effects, and significantly reduced the incidence of adverse reactions, especially in the elderly population, while enhancing humoral and cellular immune responses.
Smart Images
Figure CN119350506B_ABST